We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A novel interaction between HER2/neu and cyclin E in breast cancer.
- Authors
Mittendorf, E. A.; Liu, Y.; Tucker, S. L.; McKenzie, T.; Qiao, N.; Akli, S.; Biernacka, A.; Meijer, L.; Keyomarsi, K.; Hunt, K. K.
- Abstract
HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with HER2-overexpression and high levels of cyclin E had decreased 5-year disease-specific survival compared with low levels of cyclin E (14% versus 89%, P<0.0001). In vitro studies were performed in which HER2-mediated activity in HER2-overexpressing breast cancer cell lines was downregulated by transfection with HER2 small interfering RNA or treatment with trastuzumab. Cyclin E expression levels were determined by western blot analysis, and functional effects analyzed using kinase assays, MTT assays were used to assess cell viability as a marker of proliferation and fluorescence-activated cell sorting analysis was used to determine cell cycle profiles. Decreased HER2-mediated signaling resulted in decreased expression of cyclin E, particularly the low molecular weight (LMW) isoforms. Decreased HER2 and LMW cyclin E expression had functional consequences, including decreased cyclin E-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the G1 phase. In vivo studies performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzumab on cyclin E expression. Given the relationship between HER2 and cyclin E, in vitro clonogenic assays were performed to assess combination therapy targeting both proteins. Isobologram analysis showed a synergistic interaction between the two agents (trastuzumab targeting HER2 and roscovitine targeting cyclin E). Taken together, these studies show that HER2-mediated signaling effects LMW cyclin E expression, which in turn deregulates the cell cycle. LMW cyclin E has prognostic and predictive roles in HER2-overexpressing breast cancer, warranting further study of its potential as a therapeutic target.
- Subjects
CYCLINS; BREAST cancer; CELL cycle; CELL lines; SMALL interfering RNA; TRASTUZUMAB; WESTERN immunoblotting; FLOW cytometry
- Publication
Oncogene, 2010, Vol 29, Issue 27, p3896
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2010.151